• Profile
Close

End-stage renal disease and mortality outcomes across different glomerulonephropathies in a large diverse US population

Mayo Clinic Proceedings Jan 30, 2018

Sim JJ, et al. - Renal function decline, incident end-stage renal disease (ESRD), and mortality were compared among patients with 5 common glomerular diseases [focal segmental glomerulosclerosis (FSGS), membranous glomerulonephritis (MN), minimal change disease (MCD), immunoglobulin A nephropathy (IgAN), and lupus nephritis (LN)] in a large diverse population. Findings suggested significant differences in estimated glomerular filtration rate (eGFR) decline and ESRD risk among patients with 5 glomerulonephropathies. Different management strategies and expectations were thus justified with these variations in presentation and outcomes.

Methods

  • From January 1, 2000, to December 31, 2011, researchers performed a retrospective cohort study (between) of patients with glomerulonephropathy using the electronic health record of an integrated health system.
  • Among patients with 5 common glomerular diseases, eGFR change, incident ESRD, and mortality were compared.
  • They used competing risk models to determine hazard ratios for different glomerulonephropathies for incident ESRD, with mortality as a competing outcome after adjusting for potential confounders.

Results

  • Researchers identified 2350 patients with glomerulonephropathy (208 patients [9%] younger than 18 years) with a mean follow-up of 4.5±3.6 years.
  • Among these, 497 (21%) progressed to ESRD and 195 (8%) died before ESRD.
  • The median eGFR decline was 1.0 mL/min per 1.73 m2 per year; this varied across different glomerulonephropathies (P<.001).
  • They noted highest ESRD incidence (per 100 person-years) in FSGS 8.72 (95% CI, 3.93-16.72) followed by IgAN (4.54; 95% CI, 1.37-11.02), LN (2.38; 95% CI, 0.37-7.82), MN (2.15; 95% CI, 0.29-7.46), and MCD (1.67; 95% CI, 0.15-6.69).
  • They noted that compared with MCD, hazard ratios (95% CIs) for incident ESRD were 3.43 (2.32-5.08) and 2.35 (1.46-3.81), 1.28 (0.79-2.07), and 1.02 (0.62-1.68) for FSGS, IgAN, LN, and MN, respectively.
  • They noted no marked association between glomerulonephropathy types and mortality (P=.24).

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay